Literature DB >> 2012796

Cytotoxic potential of liposomes containing tumor necrosis factor-alpha against sensitive and resistant target cells.

A Nii1, D Fan, I J Fidler.   

Abstract

The purpose of these studies was to determine whether recombinant tumor necrosis factor (TNF) incorporated into liposomes produced enhanced antitumor effects against TNF-sensitive and TNF-resistant target cells. The lipid composition of liposomes influenced their binding to and endocytosis by target cells. Liposomes consisting of phosphatidylcholine and phosphatidylserine (7:3 molar ratio) bound to L929 cells and A375 human melanoma cells, albeit to different degrees. Liposomes retained encapsulated TNF for up to 48 h of incubation. TNF in liposomes lysed the TNF-sensitive A375 melanoma and L929 cells at levels similar to that mediated by free, unencapsulated TNF. Cells selected for resistance against free TNF were not sensitive to TNF in liposomes. Since liposomes concentrate in organs with high levels of reticuloendothelial activity, and TNF in liposomes retains antitumor activity, this delivery system may prove to be useful for treatment of lymph node and hepatic metastases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012796     DOI: 10.1097/00002371-199102000-00003

Source DB:  PubMed          Journal:  J Immunother (1991)        ISSN: 1053-8550


  3 in total

Review 1.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

2.  Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation.

Authors:  R L Baldwin; M L Stolowitz; L Hood; B J Wisnieski
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

3.  Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice.

Authors:  M Saito; D Fan; L B Lachman
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.